José Baselga, Renowned Oncologist, Dies at 61
José Baselga, Renowned Oncologist, Dies at 61
The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.
José Baselga, Renowned Oncologist, Dies at 61
José Baselga, Renowned Oncologist, Dies at 61

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

The cancer researcher and executive vice president of AstraZeneca’s oncology research and development is well known for his role in the development of pivotal breast cancer therapies.

Herceptin
Who Benefits from Herceptin and Other Anti-HER2 Cancer Therapies?
Who Benefits from Herceptin and Other Anti-HER2 Cancer Therapies?
Robert Fortner | Apr 12, 2020
Calls to include a new breast cancer subtype in future clinical trials reveal fundamental disagreements about HER2’s role in the disease.
Laskers Go to Immunologists, Developers of Breast Cancer Therapy
Laskers Go to Immunologists, Developers of Breast Cancer Therapy
Jef Akst | Sep 10, 2019
The 2019 Lasker medical and research awards celebrate advances in scientists’ understanding of T and B cells, Herceptin antibodies for treating breast cancer, and vaccine coverage around the globe.
A Plea to the FDA
Cristina Luiggi | Jun 21, 2012
Protesters crash the BIO conference to protest the delayed approval of a breast cancer drug.
Are Cancer Stem Cells Ready for Prime Time?
Are Cancer Stem Cells Ready for Prime Time?
Suling Liu, Hasan Korkaya, and Max S. Wicha | Apr 1, 2012
A flood of new discoveries has refined our definition of cancer stem cells. Now it’s up to human clinical trials to test if they can make a difference in patients.